@article{fbf386b41e9f4637975a1899817715dd,
title = "A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma",
abstract = "Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.",
keywords = "Antibody-drug conjugate, Drug-development, Efficacy, Immunotherapy, Monoclonal antibody",
author = "Sikander Ailawadhi and Kelly, \{Kevin R.\} and Vescio, \{Robert A.\} and Sundar Jagannath and Jeffrey Wolf and Mecide Gharibo and Taimur Sher and Leyla Bojanini and Maurice Kirby and Asher Chanan-Khan",
note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2019",
month = jan,
doi = "10.1016/j.clml.2018.08.018",
language = "English",
volume = "19",
pages = "29--34",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Elsevier Inc.",
number = "1",
}